Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | Maintenance therapy following treatment for amyloidosis

Morie Gertz • 24 Sep 2020
ISA 2020
Amyloidosis Multiple Myeloma Rare Diseases

Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses maintenance therapy following treatment for amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Morie Gertz

1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals